DNA/RNA heteroduplex technology with cationic oligopeptide reduces class-related adverse effects of nucleic acid drugs.
Ohara M, Nagata T, Hara RI, Yoshida-Tanaka K, Toide N, Takagi K, Sato K, Takenaka T, Nakakariya M, Miyata K, Maeda Y, Toh K, Wada T, Yokota T.
Ohara M, et al.
Mol Ther Nucleic Acids. 2024 Jul 31;35(3):102289. doi: 10.1016/j.omtn.2024.102289. eCollection 2024 Sep 10.
Mol Ther Nucleic Acids. 2024.
PMID: 39252874
Free PMC article.